FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 31, 2005
Meditech Pharmaceuticals Inc.
---------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 000-12561 95-3819300
- ------------------------ --------------------- -------------------
(State of Incorporation) (Commission File No.) (IRS Employer
Identification No.)
10105 E. Via Linda, #103, Scottsdale, Arizona 85258
(Address of principal execute offices, including zip code)
(480) 614-2874
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.01 Changes in Control of Registrant
--------------------------------
On January 31, 2005, Gerald N. Kern and Cynthia S. Kern sold 1,416,593
shares of common stock of Meditech Pharmaceuticals Inc. to Halter Capital
Corporation. Such stock represents 78% of all shares outstanding, and as a
result of the sale the Registrant experienced a change in control. The purchase
price of the shares was $250,000, paid in cash from the purchaser's existing
funds. Upon closing, Kevin Halter, Jr. was appointed to fill a vacancy on the
Board of Directors. The existing directors will remain in office until 10 days
following notification to stockholders of the change in control. Existing
management will be transferred to the Registrant's new subsidiary, East-West
Distributors, Inc., to continue their efforts toward receiving regulatory
approvals for new pharmaceuticals, and the Registrant will seek to diversify its
business beyond the pharmaceutical industry.
ITEM 9.01 Financial Statements and Exhibits
---------------------------------
10.1 - Stock Purchase Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 1, 2005 Meditech Pharmaceuticals, Inc.
(Registrant)
By: /s/ Gerald N. Kern
-------------------------------------
Gerald N. Kern
President and Chief Executive Officer
2
EXHIBIT INDEX
Exhibit #
10.1 Stock Purchase Agreement
3